摘要

The 2017 World Health Organization update introduced a new category of nodal peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) defined by expression of at least 2 or 3 TFH markers. Our study assesses the utility of an immunohistochemical panel of 5 TFH markers (CD10, BCL6, PD-1, CXCL13, and ICOS) for identification of TFH phenotype in angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified (NOS). Immunohistochemical for the 5 markers was performed on 22 cases of AITL and 29 cases of PTCL-NOS. Cases were reviewed for morphologic features characteristic of AITL. All AITL cases showed expression of ≥2 TFH markers. This panel resulted in reclassification of 41% PTCL-NOS cases to PTCL-TFH. Positive percent agreement for the TFH phenotype is 97% for PD1, 94% for ICOS, 44% for CD10 and CXCL13, and 29% for BCL6. Negative percent agreement for TFH phenotype is 100% for CD10, BCL6, and CXCL13, 82% for ICOS and 71% for PD1. AITL cases were more likely than PTCL-TFH cases to contain expanded CD21-positive follicular dendritic cell meshworks, clear cell cytology and polymorphous inflammatory background; however, there was a significant (P

译文

2017 世界卫生组织更新引入了一种新的淋巴结外周 T 细胞淋巴瘤，其 T 滤泡辅助表型 (PTCL-TFH) 由至少 2 或 3 个 TFH 标记的表达定义。我们的研究评估了由 5 个 TFH 标记 (CD10 、 BCL6 、 PD-1 、 CXCL13 和 ICOS) 组成的免疫组织化学小组在血管免疫母细胞 T 细胞淋巴瘤 (AITL) 中鉴定 TFH 表型的效用。和 PTCL 没有另外指定 (NOS)。对 22 例 AITL 和 29 例 PTCL-NOS 进行了免疫组织化学检测。对病例进行了 AITL 形态学特征的回顾。所有 AITL 病例均显示 ≥ 2 TFH 标记表达。该小组导致将 41% 起 PTCL-NOS 案件改叙为 PTCL-TFH。TFH 表型的阳性一致性为 PD1 的 97%，ICOS 的 94%，CD10 和 CXCL13 的 44%，bcl6 的 29%。CD10 、 BCL6 和 CXCL13 的 TFH 表型的阴性一致性为 100%，ICOS 为 82%，pd1 为 71%。AITL 病例比 PTCL-TFH 病例更容易包含扩增的 CD21-positive 滤泡树突状细胞网、透明细胞遗传学和多形性炎症背景; 然而，有显著性 (P